ScreenerHero

NTLA Intellia Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · intelliatx.com
12.60USD+7.60%Mkt Cap: 1.77B $P/E: —

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly inters…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap1.77B USD
Enterprise Value1.40B USD
Revenue (TTM)59.51M USD
Gross Profit-222.82M USD
Net Income (TTM)-412.69M USD
Revenue/Share0.50 USD
Last Price12.60 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees377
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.91
PEG—
EV/EBITDA-3.38
EV/Revenue23.55
P/S29.67
P/B2.42
EPS (TTM)-3.35
EPS (Forward)-2.57
52W Range
7.95023% of range28.25
52W High28.25 USD
52W Low7.950 USD
Profitability
Gross Margin0.00%
Oper. Margin-1472.26%
EBITDA Margin0.00%
Profit Margin-609.85%
ROE-61.47%
ROA-49.01%
Growth
Revenue Growth-46.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-394.74M USD
CapEx (TTM)1.13M USD
FCF Margin-419.83%
FCF Yield-14.15%
Net Debt-364.35M USD
Net Debt/EBITDA0.88
Balance Sheet
Debt/Equity0.14
Current Ratio6.65
Quick Ratio5.61
Book Value/Sh5.20 USD
Cash/Share3.12 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.4 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)23.11 USD
Upside (mean)+83.4%
Target Range8.000 USD – 61.00 USD
8.000+83.4% to mean61.00
# Analysts18
Ownership
Shares Out.140.13M
Float134.21M
Insiders3.84%
Institutions99.96%
Short Interest
Short Ratio13.7d
Short % Float41.97%
Short % Out.33.31%
Shares Short46.68M
Short (prev mo.)44.88M
Technical
SMA 5012.14 (+3.8%)
SMA 20012.92 (-2.5%)
Beta1.80
S&P 52W Chg15.84%
Avg Vol (30d)4.72M
Avg Vol (10d)6.37M
Technical Indicators
RSI (14)53.9
MACD-0.0018
MACD Signal-0.0453
MACD Hist.+0.0435
BB Upper12.84 USD
BB Middle12.09 USD
BB Lower11.33 USD
BB Width12.48%
ATR (14)0.7370 USD
Vol Ratio (20d)2.85x